408,889 Shares in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Purchased by Jefferies Financial Group Inc.

Key Points

• Jefferies Financial Group Inc. acquired a new stake in Bicycle Therapeutics PLC worth approximately $3.47 million, owning about 0.59% of the company as of the latest reporting period.
• Multiple institutional investors have recently modified their positions in Bicycle Therapeutics, with 86.15% of the stock currently held by institutional investors and hedge funds.
• Wall Street analysts have adjusted their target prices for Bicycle Therapeutics, with the consensus target price now at $24.22 despite mixed performance and a recent 6.2% decline in share price.

Jefferies Financial Group Inc. bought a new position in shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 408,889 shares of the company's stock, valued at approximately $3,471,000. Jefferies Financial Group Inc. owned about 0.59% of Bicycle Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Springhill Fund Asset Management HK Co Ltd bought a new position in shares of Bicycle Therapeutics during the 4th quarter worth about $1,630,000. Barclays PLC increased its holdings in shares of Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after purchasing an additional 2,345 shares during the period. Nan Fung Group Holdings Ltd increased its stake in Bicycle Therapeutics by 118.3% in the fourth quarter. Nan Fung Group Holdings Ltd now owns 68,943 shares of the company's stock valued at $965,000 after acquiring an additional 37,358 shares during the period. Long Focus Capital Management LLC bought a new stake in Bicycle Therapeutics in the fourth quarter valued at about $7,603,000. Finally, Jane Street Group LLC increased its stake in Bicycle Therapeutics by 18.9% in the fourth quarter. Jane Street Group LLC now owns 23,991 shares of the company's stock valued at $336,000 after acquiring an additional 3,811 shares during the period. Institutional investors and hedge funds own 86.15% of the company's stock.

Bicycle Therapeutics Price Performance

BCYC stock traded up $0.08 during trading hours on Tuesday, reaching $8.13. The stock had a trading volume of 24,143 shares, compared to its average volume of 322,402. The stock has a market capitalization of $563.07 million, a PE ratio of -2.59 and a beta of 1.44. The stock has a 50-day simple moving average of $8.01 and a 200 day simple moving average of $9.13. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $6.10 and a fifty-two week high of $28.67.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. B. Riley lowered their target price on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. Barclays lowered their target price on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. Royal Bank Of Canada lowered their target price on shares of Bicycle Therapeutics from $32.00 to $25.00 and set an "outperform" rating on the stock in a research note on Thursday, July 17th. Needham & Company LLC reissued a "buy" rating and issued a $29.00 target price on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. Finally, JMP Securities reduced their price target on shares of Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating on the stock in a research report on Friday, May 2nd. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Bicycle Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $24.22.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.